Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Daromun |
Trade Name | |
Synonyms | L19-IL2/L19-TNF-alpha|Darleukin/Fibromun|L19IL2/L19TNF |
Drug Descriptions |
Daromun consists of a mixture of darleukin, a recombinant IL2 linked to the fibronectin extra domain B (EDB) targeting single-chain variable fragment (L19), and fibromun, a human TNF-alpha linked to L19, which binds to cells expressing fibronectin EDB in tumor neovasculature, potentially resulting in the induction of antitumor immune response against tumor cells expressing EDB-containing fibronectin (NCI Drug Dictionary). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C154627 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Daromun | Daromun | 0 | 2 |
Daromun + Lomustine | Daromun Lomustine | 0 | 0 |
Daromun + Onfekafusp alfa | Daromun Onfekafusp alfa | 0 | 1 |